305 related articles for article (PubMed ID: 25643044)
1. Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):613-23. PubMed ID: 25643044
[TBL] [Abstract][Full Text] [Related]
2. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
Alkabbani W; Gamble JM
Drug Des Devel Ther; 2021; 15():3057-3069. PubMed ID: 34285473
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Nisly SA; Kolanczyk DM; Walton AM
Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
[TBL] [Abstract][Full Text] [Related]
4. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Nakamura I; Maegawa H; Tobe K; Tabuchi H; Uno S
Expert Opin Pharmacother; 2018 Feb; 19(3):189-201. PubMed ID: 29185822
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
[TBL] [Abstract][Full Text] [Related]
7. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Lajara R
Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
[TBL] [Abstract][Full Text] [Related]
8. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
Fonseca VA; Ferrannini E; Wilding JP; Wilpshaar W; Dhanjal P; Ball G; Klasen S
J Diabetes Complications; 2013; 27(3):268-73. PubMed ID: 23276620
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
Yang XP; Lai D; Zhong XY; Shen HP; Huang YL
Eur J Clin Pharmacol; 2014 Oct; 70(10):1149-58. PubMed ID: 25124541
[TBL] [Abstract][Full Text] [Related]
11. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
[TBL] [Abstract][Full Text] [Related]
12. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
13. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
Wang H; Yao G; Chen X; Ouyang J; Yang J
Diabetes Res Clin Pract; 2019 Nov; 157():107867. PubMed ID: 31568801
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
[TBL] [Abstract][Full Text] [Related]
15. Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
Lamos EM; Younk LM; Davis SN
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):763-75. PubMed ID: 23590413
[TBL] [Abstract][Full Text] [Related]
16. Ipragliflozin: first global approval.
Poole RM; Dungo RT
Drugs; 2014 Apr; 74(5):611-7. PubMed ID: 24668021
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
18. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
20. Canagliflozin: a new class of antidiabetic agent targeting the sodium-glucose cotransporter.
Toderika Y; Ferguson N
Cardiol Rev; 2014; 22(2):97-104. PubMed ID: 24500116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]